Skip to content

rabbit anti-DR4 (NT) polyclonal antibody 6001

$445.00

Antibody summary

  • Rabbit polyclonal to DR4 (NT)
  • Suitable for: ELISA,WB,IF,ICC
  • Isotype: IgG
  • 100 µg
SKU: 6001parent Category: Tag:
Weight1 lbs
Dimensions9 × 5 × 2 in
host

rabbit

isotype

IgG

clonality

polyclonal

concentration

1 mg/mL

applications

ICC/IF, WB

reactivity

DR4 (NT)

available sizes

100 µg

rabbit anti-DR4 (NT) polyclonal antibody 6001

antibody
Tested applications
WB,IHC,IHC,ICC/IF,ELISA
Recommended dilutions
Immunoblotting : use at 2ug/mL.

Positive control: Whole cell lysate from HeLa, K562, or Jurkat cells.

These are recommended concentrations.

Enduser should determine optimal concentration for their applications.
Immunogen
Peptide corresponding to aa 1-20 of human DR4 mature protein (accession no. ACC51226).
Size and concentration
100µg and lot specific
Form
liquid
Storage Instructions
This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
Storage buffer
PBS, pH 7.4.
Purity
peptide affinty purifcation
Clonality
polyclonal
Isotype
IgG
Compatible secondaries
goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512
goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079
goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863
goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371
goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715
goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control
Rabbit polyclonal - Isotype Control
target relevance
Protein names
Tumor necrosis factor receptor superfamily member 10A (Death receptor 4) (TNF-related apoptosis-inducing ligand receptor 1) (TRAIL receptor 1) (TRAIL-R1) (CD antigen CD261)
Gene names
TNFRSF10A,TNFRSF10A APO2 DR4 TRAILR1
Mass
50089Da
Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:26457518). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis (PubMed:19090789). Promotes the activation of NF-kappa-B (PubMed:9430227).
Subellular location
Cell membrane ; Single-pass type I membrane protein. Membrane raft. Cytoplasm, cytosol. Note=Palmitoylation is required for association with membranes.
Tissues
Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells.
Structure
Monomer (PubMed:26457518). Homooligomers and heterooligomers with TNFRSF10B (PubMed:19090789). Three TNFRSF10A molecules interact with the TNFSF10 homotrimer (PubMed:26457518). Can interact with TRADD and RIPK1. Interacts with ARAP1. In the absence of stimulation, interacts with BIRC2, DDX3X and GSK3B. The interaction with BIRC2 and DDX3X is further enhanced upon receptor stimulation and accompanied by DDX3X and BIRC2 cleavage (PubMed:18846110). Interacts with ZDHHC3 (PubMed:22240897).; (Microbial infection) Interacts with HCMV protein UL141; this interaction prevents TNFRSF10A cell surface expression.
Post-translational modification
Palmitoylated (PubMed:19090789). Palmitoylation of TNFRSF10A is required for its association with lipid rafts, oligomerization and function in TRAIL-induced cell death (PubMed:19090789). Palmitoylated by ZDHHC3 (Probable).
Domain
TOPO_DOM 2
Target Relevance information above includes information from UniProt accession: O00220
The UniProt Consortium

benchmark-antibodies_anti-dr4_nt_antibody_6001_1.gif
KO Validation in HeLa Cells
Loading: 10 µg of HeLa WT cell lysates or DR4 KO cell lysates. Antibodies: DR4 6001 (1 µg/mL) and beta-actin 3779 (1 µg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.
benchmark-antibodies_anti-dr4_nt_antibody_6001_2.gif
Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines
Loading: 15 µg of lysates per lane. Antibodies: DR4 2404 (1 µg/mL), DR4 6001 (4 µg/mL), beta-actin (1 µg/mL), and GAPDH (0.02 µg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
benchmark-antibodies_anti-dr4_nt_antibody_6001_3.gif
Western Blot Validation in Cell Lines
Loading: 15 µg of cell lysates per lane. Antibodies: DR4 6001 (4ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
benchmark-antibodies_anti-dr4_nt_antibody_6001_4.gif
Immunofluorescence Validation of DR4 in HeLa Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling DR4 with 6001 at 5 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on HeLa cells.
benchmark-antibodies_anti-dr4_nt_antibody_6001_5.gif
Immunocytochemistry Validation of DR4 in HeLa Cells
Immunocytochemical analysis of HeLa cells using anti-DR4 antibody (6001) at 2 µg/mL. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
benchmark-antibodies_anti-dr4_nt_antibody_6001_6.gif
KD Validation in SW480 Cells (Goda et al., 2008)
The expression of DR4 was knocked down via DR4 siRNA, 24 h latercells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies was disrupted. Dipyridamole up-regulated the expression of DR4.
benchmark-antibodies_anti-dr4_nt_antibody_6001_7.gif
Immunofluorescence Validation of DR4 in Rat Brain (Cantarella et al., 2014)
DR4 protein expression detected by anti-DR4 antibodies was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.
benchmark-antibodies_anti-dr4_nt_antibody_6001_8.gif
Immunocytochemistry Validation of DR4 in Human Melanoma Cells (Ekmekcioglu et al., 2008)
MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.
benchmark-antibodies_anti-dr4_nt_antibody_6001_9.gif
Immunohistochemistry Validation of DR4 in Human Colon Tumors (Devetzi et al., 2016)
DR4 expression in human colon tumors detected by anti-DR4 antibodies. Strong immunoreactivity is shown for DR4 in T167. Moderate immunoreactivity is shown for DR4 in T187.

Publications

pmidtitleauthorscitation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

relevant to this product
Western blot
IHC
ICC
#
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.